hoge/2248
更新日: 2015-10-28 (水) 18:41:56 (3097d)
I'm not working at the moment <a href=" http://www.surgiqual-institute.com/cheap-erectile-dysfunction-medication-stores-sell.pptx ">erectile dysfunction treatment pills tcm</a> GlaxoSmithKline? (GSK) plc today announced submission of supplemental New Drug Applications (NDAs) to the US Food and Drug Administration for use of dabrafenib, a BRAF inhibitor, in combination with trametinib, a MEK inhibitor. Supplemental applications were submitted to each of the currently approved NDAs for the use of each drug in combination with the other, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation. 
- ページ: hoge
- 投稿者: Gerardo?
- 優先順位: ä½
- 状態: çæ
- カテゴリー: 8727523515
- 投稿日: 2015-10-28 (水) 18:41:56
- バージョン: 4
メッセージ
I'm not working at the moment <a href=" http://www.surgiqual-institute.com/cheap-erectile-dysfunction-medication-stores-sell.pptx ">erectile dysfunction treatment pills tcm</a> GlaxoSmithKline? (GSK) plc today announced submission of supplemental New Drug Applications (NDAs) to the US Food and Drug Administration for use of dabrafenib, a BRAF inhibitor, in combination with trametinib, a MEK inhibitor. Supplemental applications were submitted to each of the currently approved NDAs for the use of each drug in combination with the other, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.
- このページを共有：
-
このページのURL：
